

EFFICACY OF PAROXETINE BUT NOT IMIPRAMINE
IN THE TREATMENT OF ADOLESCENT MAJOR DEPRESSION:
A RANDOMIZED, CONTROLLED TRIAL

by:

Martin B. Keller, MD
Neal Ryan, MD
Michael Strober, MD
Rachel Klein, PhD
Stan Kutcher, MD
Boris Birmaher, MD
Harold Koplewicz, MD
Jorge Armenteros, MD
Gabrielle Carlson, MD
Greg Clarke, PhD
Graham Emslie, MD
David Feinberg, MD
Barbara Geller, MD
Vivek Kusumakar, MD
G. Papatheodorou, MD
William Sack, MD
Karen Wagner, MD, PhD
Elizabeth Weller, MD
Rosemary Oakes, MS
James P. McCafferty, BS

Manuscript prepared by:

Sally K. Laden, MS
Scientific Therapeutics Information, Inc
Springfield, New Jersey

Manuscript prepared for:

James P. McCafferty
SmithKline Beecham Pharmaceuticals
Collegeville, Pennsylvania

Draft III
March 22, 1999

WB 202457

EFFICACY OF PAROXETINE BUT NOT IMIPRAMINE
IN THE TREATMENT OF ADOLESCENT MAJOR DEPRESSION:
A RANDOMIZED CONTROLLED TRIAL

by:

Martin B. Keller, MD
Neal Ryan, MD
Michael Strober, MD
Rachel Klein, PhD
Stan Kutcher, MD
Boris Birmaher, MD
Harold Koplewicz, MD
Jorge Armenteros, MD
Gabrielle Carlson, MD
Greg Clarke, PhD
Graham Emslie, MD
David Feinberg, MD
Barbara Geller, MD
Vivek Kusumakar, MD
G. Papatheodorou, MD
William Sack, MD
Karen Wagner, MD, PhD
Elizabeth Weller, MD
Rosemary Oakes, MS
James P. McCafferty, BS

The academic degrees and affiliations for all authors to be listed here.

Corresponding author: Martin B. Keller, MD, Department of Psychiatry and Human Behavior, Brown University School of Medicine, 345 Blackstone Boulevard, Providence, RI 02906, telephone: (401) 455-6430, fax: (401) 450-6441, e-mail: XXXXXXX.¹

Financial support for this study was provided by SmithKline Beecham Pharmaceuticals. Editorial assistance in manuscript preparation provided by Sally K. Laden, MS.

Submitted to: *Journal of the American Medical Association (JAMA)*
Date Submitted: XX/XX/99

¹ Dr Keller: please provide an email address as required by JAMA.

WB 202458

ABSTRACT (404)

Context: Depression is a highly prevalent disorder among adolescents, and suicide is the second leading cause of death in this age group.

Antidepressant treatment of adolescent depression is vastly understudied. Tricyclic antidepressants, with their attendant cardiotoxicity and lethality in overdose, are the best studied agents to date. Until now there have been no double-blind, placebo-controlled comparisons of a selective serotonin reuptake inhibitor with placebo-controlled comparisons of a tricyclic antidepressant.

Objective: To compare the efficacy and safety of paroxetine and imipramine with placebo in the treatment of adolescent depression.

Design: Eight-week, multicenter, randomized, double-blind trial.

Setting and Subjects: 275 adolescent subjects (ages 12 to 18 years) meeting DSM-III-R criteria for major depression were randomized to treatment at 10 centers in the United States and 2 in Canada.

Intervention: After a 7- to 10-day screening period, subjects received a double-blind 8-week course of paroxetine, imipramine, or matching placebo. Paroxetine was administered in doses of 20 mg to 40 mg/day. Imipramine therapy was gradually titrated upwards, based on tolerance and response, to a maximum of 300 mg/day.

Main Outcome Measures: Eight depression-related variables were assessed: 1) Remission at endpoint (HAMD score \leq 8 at endpoint); 2) Response at endpoint (a HAMD score \leq 8 or a \geq 50% reduction in baseline HAMD score); 3) depressed mood item of HAMD; 4) depression item of K-SADS-L; 5) CGI improvement scores of 1 (very much improved) or 2 (much improved); 6) 9-item depression subscale of K-SADS-L; 7) mean CGI improvement scores; and 8) change from baseline HAMD total score. Measures of behavior (Autonomous Function Checklist; Self Perception Profile; Sickness Impact Scale) were also assessed.

Results: Efficacy was demonstrated for paroxetine, with significantly greater improvement across measures of remission, HAM-D depressed mood item, K-SADS-L depressed mood item, and CGI score of 1 or 2. In contrast, the therapeutic response to imipramine was not significantly different than placebo for any of the measures of antidepressant efficacy. Neither paroxetine nor imipramine differed from placebo across the behavioral measures, however, improvements over baseline were achieved for each treatment group. Paroxetine was very well-tolerated, with adverse effects that were similar in spectrum and severity as observed during treatment of adults. Imipramine was less well-tolerated, with 31.5% of subjects withdrawing from the study due to adverse effects. Of the subjects stopping imipramine therapy, nearly one-third did so because of adverse cardiovascular effects, including tachycardia, postural hypotension, and ECG abnormalities.

Conclusions: Paroxetine is a safe and effective treatment of major depressive disorder in the adolescent patient. Further studies are warranted to determine the optimal dose and duration of therapy.

WB 202460

INTRODUCTION

The treatment of depression in adolescents is an area of burgeoning research interest. Unfortunately, few well-controlled, large-scale, randomized assignment clinical trials have been conducted in this population to date. In addition, studies to date often lack the optimal intensity and duration of pharmacotherapy for severely ill teens with affective illness (Strober et al, 1998). Data from the 1,769 adolescents and young adult participants in the National Comorbidity Survey (Kessler et al, 1998) indicate a lifetime prevalence rate of 15.3% for major depression, comparable to the 17% lifetime prevalence of depression in adults (Kessler et al, 1994). As with adults, the course of major depression in adolescents is often characterized by protracted episodes, frequent recurrence, and impairment in social and academic domains (Rao et al, 1995).² Suicide is the second leading cause of death in adolescents, and the rates of suicide in this age group have tripled in the last three decades (Keller et al, 19XX; Kovacs et al, 19XX).³

² Dr Ryan: please confirm that this is the paper you asked to be included.

³ Dr Keller: please provide complete citations.

The efficacy of tricyclic antidepressants have been investigated in at least 11 double-blind, randomized studies (Dulcan et al, 1998; Ryan and Varma, 1998), none demonstrating superiority of active treatment over placebo.

However, methodological deficiencies in these studies, including very small sample sizes and heterogeneity of diagnostic composition of subjects, limit statistical inference and generalizability of the findings. At the same time, cardiovascular effects and lethality in overdose associated with the tricyclic agents has greatly limited their use in clinical practice.

Intentional overdose of cardiotoxic tricyclic antidepressants is a particularly salient concern for younger patients among whom use of medications in suicide attempts is a major clinical problem. These concerns are believed to limit prescription of these medications in this population.

Since their commercial availability, the safety, tolerability, and effectiveness of selective serotonin reuptake inhibitors (SSRIs) in treating major depression in adolescents have been noted in several open-label reports (Apter et al, 1994; Boulos et al, 1992; Masi et al, 1997; McConville et al, 1996; Rey-Sanchez et al, 1997; Rodriguez-Ramos et al, 1996; Simeon et al, 1998). Although controlled trials remain the standard against which

effectiveness is determined, only three have been reported (Emslie et al, 1997; Simeon et al, 1996; Strober et al, 1999). One placebo-controlled study (Emslie et al, 1997) showed a drug-placebo difference on the Clinical Global Impressions global improvement scale of 23%. Another study, employing a historical case control design (Strober et al, 1999) demonstrated greater efficacy of fluoxetine compared to imipramine in a severely ill, inpatient population of adolescents with major depression. We now report principal findings from the first double-blind, placebo-controlled comparison of a selective serotonin reuptake inhibitor, paroxetine, and a placebo-controlled comparison with a tricyclic antidepressant, imipramine.

METHODS

Study Design

This was an 8-week, multicenter, double-blind, randomized, parallel-design, placebo-controlled comparison of paroxetine and imipramine therapy in adolescents with major depression. The trial was conducted at 10 centers in the United States and two in Canada. Four hundred twenty five subjects were screened for eligibility, and 275 subjects were randomized to active

WB 202453

treatment. The trial was conducted in accordance with good Clinical Practices and the Helsinki Declaration. All subjects and their parent(s) provided written informed consent before entry into the study.

Patient Eligibility

Male and female subjects, ages 12 through 18 years of age, fulfilling the *Diagnostic and Statistical Manual of Mental Disorders, Third Edition, revised* (DSM-III-R) (American Psychiatric Association, 1987) criteria for a current episode of major depression of at least 8 weeks in duration were enrolled. Major depression was diagnosed by structured interview using the juvenile version of the Schedule for Affective Disorders and Schizophrenia for Adolescents - Lifetime Version (K-SADS-L) rating scale, which has been modified from the adult SADS assessment technique (Endicott and Spitzer, 1978). The K-SADS-L uses separate patient and parent reports to assess lifetime presence of affective and schizophrenic disorders, as well as the full range of childhood and adolescent psychopathological conditions. In addition to fulfilling DSM-III-R criteria for major depression, subjects were required to have a total score on the 17-item Hamilton Depression Rating (HAM-D) scale of at least 12, a Child Global Assessment Scale (C-GAS) score

WB 202464

less than 60, and an Intelligence Quotient (IQ) score of at least 80, as determined by the Peabody Picture Vocabulary Test. All subjects were medically healthy.

Potential participants in the study were screened initially by telephone, and candidates who were considered likely to meet diagnostic criteria were evaluated immediately at the study site. Adolescents and parents were interviewed separately. For those cases where there existed a significant discrepancy between information provided by the adolescent and the parent, the clinician met with both to discuss the information obtained and then rendered a rating. Eligible subjects and their parent(s) had to reach agreement with the site investigator that the subject had a disorder requiring treatment. In cases where the diagnosis was not certain, audiotapes of the screening interview were reviewed and the diagnosis was verified further by an independent expert from another participating site prior to certifying study eligibility.

Subjects with a current or lifetime DSM-III-R diagnosis of bipolar disorder, schizo-affective disorder, eating disorder, alcohol or substance use

disorder, obsessive-compulsive disorder, autism/pervasive mental disorder, or organic brain disorder were excluded from consideration. A diagnosis of post-traumatic stress disorder within 12 months of recruitment was also exclusionary, as was current suicidal ideation, with intent or specific plan, a history of suicide attempts by drug overdose, any medical condition in which the use of an antidepressant was contraindicated, current psychotropic drug use, an adequate trial of antidepressant medication within 6 months of study entry, or exposure to either investigational drug use within 30 days of study entry or within 5 half-lives of the drug. Females who were pregnant or breastfeeding, and those who were sexually active and not using reliable contraception were also excluded.

Blinding, Randomization, and Treatment

All subjects underwent a 7- to 10-day screening phase to determine persistence of entry diagnostic and severity eligibility criteria and to obtain baseline global functioning scores, physical examination, and clinical laboratory studies. Using a computer-generated list, subjects who still met entry criteria were randomized to an 8-week course of treatment with paroxetine, imipramine, or placebo in a 1:1:1 ratio. Tablets were

WB 202466

overencapsulated in matching capsules to preserve medication blinding.

Subjects assigned to paroxetine treatment received 20 mg per day in the morning for weeks 1 through 4. Optional dosage increases to 30 mg paroxetine per day were allowed at week 5 and to 40 mg per day at weeks 6 through 8 if deemed necessary by the investigator. Imipramine treatment was initiated with a forced titration schedule in which subjects received daily doses of 50 mg during week 1, 100 mg (in divided doses) during week 2, 150 mg during week 3, and 200 mg during week 4. Thereafter, optional dosage increases to 250 mg per day for week 5 and to 300 mg per day for weeks 6 through 8 were allowed if judged necessary by the investigator.

Supportive case management was provided to all subjects at each weekly clinic

visit according to the method described by Fawcett (Fawcett et al, 1987).

Such management was limited to clinical support and observation of treatment effects and strictly prohibited interpersonal or cognitive/behavioral psychotherapeutic interventions.

WB 202467

Efficacy and Safety Evaluation

Following randomization, subjects were seen at weekly intervals and evaluated with standardized instruments and global assessments for efficacy. Eight depression-related variables were assessed a priori: 1) remission at endpoint; 2) response at endpoint; 3) change in the depressed mood item of the HAM-D; 4) change in the depression item of the K-SADS-L; 5) CGI improvement scores of 1 (very much improved) or 2 (much improved); 6) change in the 9-item depression subscale of the K-SADS-L; 7) mean Clinical Global Impressions (CGI) improvement scores; and 8) change from baseline in HAM-D total score. Subjects were considered to be responders if, at the end of treatment, they had achieved a HAM-D score ≤ 8 or a $\geq 50\%$ reduction in baseline HAM-D score. Remission was defined as a HAM-D score ≤ 8 at endpoint.

Behavioral measures consisted of 1) Autonomous Function Checklist, completed by the parent, that assessed the subject's autonomy in performing daily activities (Sigafos et al, 1988); 2) Self Perception Profile, completed by the subject to determine self-esteem (Harter, 1988); and 3) Sickness Impact Scale, completed by the subject, to measure present health and quality of life (Bergner et al, 1981).

WB 202468

Adverse events, heart rate, blood pressure, and body weight were determined at each weekly visit. Rhythm strip EKGs were obtained at each visit, and 12-lead EKGs were obtained during the screening phase and at weeks 4 and 8. Routine clinical laboratory studies were conducted during the screening phase and at week 8, or upon study withdrawal.

Changes in cardiovascular parameters required dosage reduction. Doses were reduced by 10 mg for paroxetine doses of 30 mg or 40 mg; subjects at 20 mg paroxetine were withdrawn from the study. Similarly, imipramine doses of 250 mg or 300 mg per day were reduced by 50 mg, and subjects at ≤ 200 mg imipramine were withdrawn from the study. Cardiovascular parameters necessitating dosage reduction or study withdrawal were defined prospectively as heart rate ≥ 110 beats per minute (bpm) at two consecutive visits, or heart rate ≥ 130 bpm at a single visit; systolic blood pressure ≥ 140 mmHg/diastolic blood pressure < 85 mmHg; PR interval ≥ 0.21 seconds; QRS interval ≥ 0.12 seconds and $\geq 150\%$ of baseline, or QTc interval ≥ 0.48 seconds.

WB 202469

Blood samples were obtained at weeks 4 and 8 for determination of plasma concentrations of imipramine, desmethylimipramine (the major, pharmacologically active, metabolite of imipramine), and paroxetine. Subjects were withdrawn from the study if the combined imipramine and desmethylimipramine concentration exceeded 500 ng/mL. The paroxetine plasma concentration cut-off point for study withdrawal was XXXX.⁴

Statistical Methods

Changes from baseline to endpoint in the total HAM-D score, CGI improvement scale, and K-SADS-L were analyzed by using a 2-factor analysis of variance (ANOVA) implemented using the general linear models (GLM) procedure of the SAS system with a model including effects for treatment and investigator. The model included terms for treatment group, investigator, and investigator-by-treatment interaction. Categorical variables, such as the percentage of subjects responding to treatment, were analyzed using logistic analysis implemented in the categorical modeling procedure (CATMOD) of the SAS system with a model including effects for treatment and investigator. Pair-wise

⁴ SB Reviewers: Is this statement necessary? If so, the cut-off point was not included in the Clinical Report.

comparisons between treatments were made at the 0.05 level of significance using the CONTRAST statement.

All statistical tests comparing active treatments to placebo were two-tailed and performed at an alpha level of 0.05. Using a power of 0.80 from affect size data from adult studies, to detect a difference between active treatments and placebo, a sample size of 300 subjects (later modified to 275) was determined a priori as the target recruitment.⁵ Efficacy analyses were carried out on the sample of randomized subjects with at least one post-baseline efficacy evaluation (N=275, referred to herein as the "efficacy population"). For subjects who did not complete the entire study, endpoint was defined as the last evaluation during treatment and was used as an estimate of the missing data (ie, last observation carried forward); this was the primary population reported. Data are reported as mean values (\pm standard deviation or standard error) and 95% confidence intervals are reported where appropriate.

⁵ SB Reviewers: Please confirm accuracy of this statement.

RESULTS

Of 425 subjects who were screened, 275 were enrolled in the study and randomized for treatment (Figure 1). Treatment groups were well-matched with regard to demographic characteristics and psychiatric profile (Table 1). A typical subject was female, 15 years of age, and Caucasian. Most subjects had a positive family history for depression and had experienced only one prior episode of major depression. The mean duration of the current depressive episode was over one year, with a mean baseline HAM-D total score between 18 and 19. Approximately 30% of subjects exhibited features of melancholic or endogenous depression, and 20% had features of atypical depression. Psychiatric comorbidity was common; anxiety disorders, such as separation anxiety and social anxiety disorder, and externalizing disorders, occurred in approximately 20% to 30% of subjects.

Premature Discontinuation

A total of 190 subjects (69% of 275) completed the 8-week study (Figure 1). Premature withdrawal rates were 28% for paroxetine, 40% for imipramine, and 24% for placebo. Study withdrawal due to adverse effects was the most common

WB 202472

reason for discontinuation in the paroxetine (9.7%) and imipramine (31.5%) groups, respectively. Premature study discontinuation due to adverse effects occurred at a rate of 6.9% in the placebo group. Cardiac adverse effects led to withdrawal among 14% of subjects in the imipramine group (13 subjects). Protocol violation, including lack of compliance, was the most common reason for withdrawal in the placebo group (8.0%).

Efficacy Results

PAROXETINE IS DRUG
Of the 8 depression-related variables, paroxetine separated statistically from placebo along 4 of the parameters: remission, HAM-D depressed mood item, K-SADS-L depressed mood item, and CGI score of 1 (very much improved) or 2 (much improved) and trended toward statistical significance on two measures: K-SADS-L 9-item depression subscore and mean CGI score (Table 3). The response to imipramine was not significantly different than that for placebo across any of the 8 depression-related variables.

Subjects in all treatment groups exhibited progressively greater remission rates, defined as a HAM-D total score ≤ 8 at study endpoint, during the first 4 weeks of the study. Remission was achieved in 63.3% of paroxetine subjects

(57/90; $P=.019$ versus placebo), 50% of imipramine subjects (47/94; $P=.574$ versus placebo), and 46% of placebo subjects (40/87) at endpoint (Figure 2). Among patients who completed 8 weeks of treatment, 76.1% of paroxetine subjects (51/67; $P=.019$ versus placebo), 64.3% of imipramine subjects (36/56; $P=.44$ versus placebo), and 57.6% of placebo subjects (38/66) achieved remission. In the paroxetine group, 65.6% ($P=.02$) of patients were considered very much or much improved on the CGI; rates for the imipramine and placebo groups were 52.1% ($P=.64$) and 48.3%, respectively. Improvement in baseline depressed mood as measured by the HAMD and the K-SADS-L depressed mood items was significantly greater than placebo in the paroxetine group, but not the imipramine group. Improvements in the K-SADS-L depression subscore ($P=.065$) and mean CGI score ($P=.094$) trended toward statistical significance in the paroxetine group, but not in the imipramine group ($P=.98$ and $P=.89$, respectively) (Table 3).

cf 20
Although neither paroxetine nor imipramine separated statistically from placebo across the behavioral measures, improvements over baseline were achieved for each active treatment group. Placebo-treated subjects also

improved along the behavioral measures, but to a lesser extent than patients in the active-treatment groups (Table 4).

Dosage Titration

Nearly half of subjects in the paroxetine group remained at the initial starting dose of 20 mg per day (48%). Mean dose at study endpoint for paroxetine was 28.0 mg (s.d. \pm 8.54 mg) and for imipramine was 205.8 mg (s.d. \pm 63.94 mg). The most common "doses" of placebo (administered as divided doses) were 4 capsules per day (31.0%) and 6 capsules per day (41.4%).

Adverse Effects

Paroxetine was well-tolerated in this adolescent population. The most common adverse effects reported during paroxetine therapy were headache, nausea, dizziness, dry mouth, and somnolence (Table 5). These occurred at rates that were similar to the placebo group with the exception of somnolence, which occurred at rates of 17.2% for paroxetine and 3.4% for placebo. Dizziness, dry mouth, headache, nausea, and tachycardia were most commonly reported during imipramine treatment. Tremor occurred in 10.8% of paroxetine-, 14.7% of imipramine-, and 2.3% of placebo-treated subjects.

Adverse effects in all treatment groups occurred most often during the first week of therapy. Dosage reductions were most often required for somnolence, insomnia, and restlessness among paroxetine-treated subjects. Dry mouth, constipation, and tremor were the most common adverse effects leading to imipramine dose reductions. Premature withdrawal from the study due to adverse effects occurred at rates of 9.7% for paroxetine, 31.5% for imipramine, and 6.9% for placebo (Figure 1). Clinically significant increases or decreases in body weight were not observed among any of the three treatment arms of this study.

Of subjects in the imipramine group who stopped therapy due to adverse effects, nearly one-third (13.7%) did so because of cardiovascular effects, including tachycardia, postural hypotension, and prolonged QT interval. Mean standing heart rate increased by 17 beats per minute over baseline among subjects treated with imipramine. Neither paroxetine nor placebo was associated with changes in heart rate.

COMMENT

This is the first study to compare efficacy of an SSRI and a tricyclic antidepressant with placebo in the treatment of adolescent major depressive disorder. Paroxetine was numerically superior to placebo on all 8 of the prospectively defined measures of efficacy and significantly more effective than placebo with regard to achievement of full remission and a CGI score of 1 (very much improved) or 2 (much improved), and improvements in the depressed mood items of the HAMD and the K-SADS-L. Although several outcome measures failed to separate significantly from placebo, trends toward statistical significance were observed. A surprisingly large placebo response, which may be attributed to the weekly supportive case management sessions, is a rational explanation for the statistical findings in this study.

This demonstration of efficacy for paroxetine is in accordance with findings of open-label studies of SSRIs (Apter et al, 1994; Boulos et al, 1992; Masi et al, 1997; McConville et al, 1996; Rey-Sanchez et al, 1997; Rodriguez-Ramos et al, 1996; Simeon et al, 1998), a retrospective review of fluoxetine (Jain

et al, 1992), and results from placebo-controlled (Emslie et al, 1997) and historical case-control (Strober et al, 1999) studies. These findings of efficacy for paroxetine and other SSRIs are notable in that randomized, double-blind, placebo-controlled trials (Geller et al, 1990, 1989; Hughes et al, 1990; Kashani et al, 1984; Klein et al, 1992; Kramer and Feiguine, 1981; Kutcher et al, 1994; Kye et al, 1996; Petti and Law, 1982; Preskorn et al, 1987; Puig-Antich et al, 1987) and one meta-analysis (Hazell et al, 1995) have not shown efficacy for the tricyclic antidepressants in the treatment of adolescent depression. Because tricyclic antidepressants are no longer under patent protection and are associated with an unacceptably high risk of cardiotoxicity, especially in children, further controlled studies of these agents are not likely to be conducted. As such, future research involving noradrenergic antidepressants not yet clinically available will be required to address the question of preferential efficacy of the SSRIs in this age group.

Our study employed a flexible-dose design in which doses could be adjusted based on clinical response and tolerability. Roughly half of subjects were maintained at a 20-mg daily dose of paroxetine. The mean daily dose of

paroxetine in this study was 28 mg, which is comparable to the findings of flexible-dose trials in adults (Claghorn, 1992; Cohn and Wilcox, 1992; Dunbar et al, 1991; Fabre, 1992; Feighner and Boyer, 1992; Shrivastava et al, 1992; Smith and Glaudin, 1992).

The adverse effect profile of paroxetine in this adolescent population was concordant with that reported in studies of adult patients with depression (Claghorn, 1992; Cohn and Wilcox, 1992; Dunbar et al, 1991; Fabre, 1992; Feighner and Boyer, 1992; Shrivastava et al, 1992; Smith and Glaudin, 1992). Adverse cardiovascular effects were not observed in subjects treated with paroxetine. In contrast, tachycardia, postural hypotension, and prolongation of QT intervals during imipramine therapy resulted in treatment discontinuation in one-third of the 31.5% of subjects who prematurely stopped treatment with the tricyclic antidepressant.

In conclusion, the findings of this study provide evidence of the effectiveness and safety of the selective serotonin reuptake inhibitor, paroxetine, in the treatment of adolescent depression. Additional studies are called for to define the optimal length of therapy and dose of selective serotonin reuptake inhibitors in this population.

REFERENCES

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 3rd ed, revised. Washington, DC: American Psychiatric Association Inc; 1987.

Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: Development and final revision of a health status measure. *Med Care*. 1981;19:787-805.

Claghorn J. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. *J Clin Psychiatry*. 1992;53:33-35.

Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. *J Clin Psychiatry*. 1992;53:52-56.

Dulcan MK, Bregman J, Weller EB, Weller R. Treatment of childhood and adolescent disorders. In: Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology*. 2nd ed. Washington, DC: American Psychiatric Press, Inc; 1998:803-850.

Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine, and placebo in depressed outpatients. *Br J Psychiatry*. 1991;159:394-398.

Emslie GJ, Rush J, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. *Arch Gen Psychiatry*. 1997;54:1031-1037.

WB 202480

Endicott J, Spitzer RL. A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. *Arch Gen Psychiatry*. 1978;35:837-844.

Fabre LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. *J Clin Psychiatry*. 1992;53:40-43.

Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management - imipramine/placebo administration manual. *Psychopharmacol Bull*. 1987;23:309-324.

Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. *J Clin Psychiatry*. 1992;53:44-47.

Geller B, Cooper TB, McCombs HG, Graham D, Wells J. Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. *Psychopharmacol Bull*. 1989;25:101-108.

Geller B, Cooper TB, Graham DL, Marsteller FA, Bryant DM. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. *Psychopharmacol Bull*. 1990;26:85-90.

Harter S. *Manual for the Self Perception Profile for Adolescents*. University of Denver, Denver, CO;1988.

Hughes CW, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S. The effect of concomitant disorders in childhood depression on predicting treatment response. *Psychopharmacol Bull*. 1990;26:235-238.

Kashani JH, Shekim WO, Reid JC. Amitriptyline in children with major depressive disorder: a double-blind crossover pilot study. *J Am Acad Child Psychiatry*. 1984;23:348-351.

Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. *Depression & Anxiety*. 1998;7:3-14.

Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. *Arch Gen Psychiatry*. 1994;51:8-19.

Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. *J Am Acad Child Adolesc Psychiatry*. 1992;31:21-28.

Kramer AD, Feiguine RJ. Clinical effects of amitriptyline in adolescent depression. A pilot study. *J Am Acad Child Adolesc Psychiatry*. 1981;20:636-644.

Kutcher S, Boulos C, Ward B, et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry*. 1994;33:686-694.

Kye CH, Waterman GS, Ryan ND, et al. A randomized, controlled trial of amitriptyline in the acute treatment of a major depression. *J Am Acad Child Adolesc Psychiatry*. 1996;35:1139-1144.

Masi G, Marcheschi M, Pfanner P. Paroxetine in depressed adolescents with intellectual disability: an open label study. *J Intell Dis Res.* 1997;41:268-272.

McConville BJ, Minnery KL, Sorter MT, et al. An open study of the effects of sertraline on adolescent major depression. *J Child Adol Psychopharmacol.* 1996;6:41-51.

Petti TA, Law WD. Imipramine treatment of depressed children: a double-blind pilot study. *J Clin Psychopharmacol.* 1982;2:107-110.

Preskorn SH, Weller EB, Hughes CW, Weller RA, Bolte K. Depression in prepubertal children: dexamethasone nonsuppression predicts differential response to imipramine vs. placebo. *Psychopharmacol Bull.* 1987;23:128-133.

Puig-Antich J, Perel JM, Lupatkin W, et al. Imipramine in prepubertal major depressive disorders. *Arch Gen Psychiatry.* 1987;44:81-89.

Rao U, Ryan ND, Birmaher B, et al. Unipolar depression in adolescents: clinical outcome in adulthood. *J Am Acad Child Adol Psychiatry.* 1995;34:566-578.

Rey-Sanchez F, Gutierrez-Casares JR. Paroxetine in children with major depressive disorder: an open trial. *J Am Acad Child Adol Psychiatry.* 1997;36:1443-1447.

Rodriguez-Ramos P, de Dios-Vega JL, San Sebastian-Cabases J, Sordo-Sordo L, Mardomingo-Sanz MJ. Effects of paroxetine in depressed adolescents. *Eur J Clin Res.* 1996;8:49-61.

Ryan ND, Varma D. Child and adolescent mood disorders - experience with serotonin-based therapies. *Biol Psychiatry*. 1998;44:336-340.

Shrivastava RK, Shrivastava SHP, Overweg N, Blumhardt CL. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. *J Clin Psychiatry*. 1992;53:48-51.

Sigafoos AD, Feinstein CB, Damond M, Reiss D. The measurement of behavioral autonomy in adolescence: The autonomous functioning checklist. *Adoles Psychiatry*. 1988;15:432-462.

Simeon JG, Nixon MK, Milin RP, Spenst W, Smith D. Sertraline in adolescent depression and dysthymia: a six-month open trial. Presented at the 151st Annual Meeting of the American Psychiatric Association; May 30 - June 4, 1998; Toronto, Canada.

Smith WT, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. *J Clin Psychiatry*. 1992;53:36-39.

Strober M, DeAntonio M, Schmidt-Lackner S, Pataki C, Freeman R, Rigali J, Rao U. The pharmacotherapy of depressive illness in adolescents: IV. An open-label comparison of fluoxetine with imipramine treated historical controls. *J Clin Psychiatry*. 1999.⁵

⁵ Dr Strober: Is this paper in press? It hasn't appeared yet on MedLine. Kindly provide the complete citation.

Strober M, De Antonio M, Lampert C, Diamond J. Intensity and predictors of treatment received by adolescents with unipolar major depression prior to hospital admission. *Depr/Anx.* 1998;7:40-46.

WEB 202485

Table 1. Demographic characteristics and mean baseline depression scores for 275 randomized subjects

Parameter	Paroxetine N=93	Imipramine N=95	Placebo N=87
Gender M/F	35/58	39/56	30/57
Mean age \pm s.d. (y)	14.8 \pm 1.6	14.9 \pm 1.6	15.1 \pm 1.6
Race			
Caucasian	77 (82.8%)	83 (87.4%)	70 (80.5%)
African-American	5 (5.4%)	3 (3.2%)	6 (6.9%)
Asian-American	1 (1.1%)	2 (2.1%)	2 (2.3%)
Other	10 (10.8%)	7 (7.4%)	9 (10.3%)
Child Global Assessment Scale (mean \pm s.d.)	42.7 \pm 7.5	42.5 \pm 7.4	42.8 \pm 8.3
Duration of current depressive episode in months (mean \pm s.d.)	14 \pm 18	14 \pm 18	13 \pm 17
Number of prior depressive episodes			
1	81%	79%	77%
2	12%	14%	14%
≥ 3	7%	6%	8%

Family history of major depression	86%	90%	95%
Age at onset of first episode in years (mean \pm s.d.)	13.1 \pm 2.8	13.2 \pm 2.7	13.5 \pm 2.3
Mean baseline HAM-D total score	18.98 \pm 0.43	18.11 \pm 0.43	18.97 \pm 0.44
Features of melancholic/ Endogenous depression	36%	35%	40%
Features of atypical depression	25%	16%	9%
Comorbid psychiatric diagnosis			
Any diagnosis	41%	50%	45%
Anxiety disorder ^a	19%	26%	28%
Externalizing disorder ^b	25%	26%	20%

^a Includes separation anxiety, panic \pm agoraphobia, agoraphobia, social anxiety disorder, generalized anxiety disorder.

^b Includes conduct disorder, oppositional defiant disorder, and attention deficit/hyperactivity.

Table 2. Medication Doses at Study Endpoint (N=275)

Treatment Group	Daily Dose at Endpoint (mg)	Number of Subjects (%)
Paroxetine N=93	20 mg	45 (48%)
	30 mg	22 (23.7%)
	40 mg	26 (28.0%)
	Mean dose in mg \pm s.d.	28.0 \pm 8.54 mg
Imipramine N=95	50 mg	3 (3%)
	100 mg	11 (11.5%)
	150 mg	5 (5.3%)
	200 mg	45 (47.4%)
	250 mg	15 (15.8%)
	300 mg	16 (16.8%)
	Mean dose in mg \pm s.d.	205.8 \pm 63.94 mg
Placebo N=87	2 capsules	5 (5.7%)
	3 capsules	5 (5.7%)
	4 capsules	27 (31.0%)
	5 capsules	14 (16.1%)
	6 capsules	36 (41.4%)

Table 3. Summary of depression-related variables in adolescents with major depression* who were treated with paroxetine, imipramine, or placebo†

Variable	Paroxetine			Imipramine			Placebo		
	Mean	(s.e.)	N	P	Mean	(s.e.)	N	P	Mean (s.e.) N
Remission††									
Week 8 endpoint	63.3%	(-)	90	.019	50.0%	(-)	94	.574	46.0% (-) 87
Response††									
Week 8 endpoint	66.7%	(-)	90	.112	58.5%	(-)	94	.61	55.2% (-) 87
HAMD Depressed Mood Item									
Baseline	2.99	(0.08)	90		2.79	(0.08)	94		2.86 (0.08) 87
Week 8 endpoint	0.99	(0.14)	90	.001	1.17	0.14)	94	.135	1.53 (0.14) 87
K-SADS-L Depressed Mood Item									
Baseline	4.57	(0.09)	83		4.29	0.09)	87		4.63 (0.09) 85
Week 8 endpoint	2.37	(0.18)	83	.049	2.52	0.18)	87	.868	2.90 (0.18) 85
CGI Score of 1 or 2									
Week 8 endpoint	65.6%	(-)	90	.02	52.1%	(-)	94	.642	48.3% (-) 87
K-SADS-L 9-Item Depression Subscore									
Baseline	28.25	(0.52)	83		27.54	0.51)	88		28.84 (0.52) 85
Week 8 endpoint	16.59	(0.84)	83	.065	17.99	0.83)	88	.984	19.27 (0.83) 85
Mean CGI score									
Week 8 endpoint	2.37	(0.16)	90	.094	2.70	0.15)	94	.895	2.73 (0.16) 87
HAMD Total Score									
Baseline	18.98	(0.43)	90		18.11	(0.43)	94		18.97 (0.44) 87
Week 8 endpoint	8.24	(0.81)	90	.133	9.2	(0.81)	94	.873	9.88 (0.83) 87

* The last evaluation during treatment for subjects who did not complete the entire study (ie, the last observation carried forward) is reported.

† Data presented as mean (+/-) s.e.

†† Remission = HAMD total score 8 at endpoint; Response = HAMD total score 8 or a 50% reduction in baseline HAMD score; CGI score of 1 = very much improved; CGI score of 2 = much improved

** SB Reviewers: are CI data available?

WB 202489

Adolescent Depression Study (PAR 329)/DOC 64976/Page 33

PAR000212920

Table 4. Summary of behavioral measures in adolescents with major depression* who were treated with paroxetine, imipramine, or placebo†

Variable	Paroxetine			P	Imipramine			P	Placebo		
	Mean	(s.e.)	N		Mean	(s.e.)	N		Mean	(s.e.)	N
Autonomous Function											
Checklist											
Baseline	91.41	(3.80)	60	.584	96.02	(3.97)	57	.719	94.18	(3.74)	62
Week 8 endpoint	106.11	(2.80)	60	.148	107.59	(2.92)	57	.546	103.48	(2.75)	62
Self Perception											
Profile											
Baseline	63.48	(2.58)	61	.418	60.87	(2.67)	60	.960	60.69	(2.52)	63
Week 8 endpoint	76.73	(2.33)	61	.542	73.94	(2.41)	60	.586	72.05	(2.27)	63
Sickness Impact											
Profile											
Baseline	30.90	(1.46)	63	.511	30.38	(1.52)	60	.363	32.17	(1.42)	65
Week 8 endpoint	19.54	(1.55)	63	.463	17.46	(1.62)	60	.143	22.32	(1.51)	65

* The last evaluation during treatment for subjects who did not complete the entire study (ie, the last observation carried forward) is reported.

† Data presented as mean (+/-) s.e.

WB 202490

Table 5. Adverse effects occurring in $\geq 5\%$ of subjects in the paroxetine, imipramine, and placebo groups

	Paroxetine	Imipramine	Placebo
Adverse effect	N=93	N=95	N=87
Cardiovascular system			
Tachycardia	2 (2.2%)	18 (18.9%)	1 (1.1%)
Postural hypotension	1 (1.1%)	13 (13.7%)	1 (1.1%)
Vasodilatation	0 (0%)	6 (6.3%)	2 (2.3%)
Chest pain	2 (2.2%)	5 (5.3%)	2 (2.3%)
Digestive system			
Dry mouth	19 (20.4%)	43 (45.3%)	12 (13.8%)
Nausea	22 (23.7%)	23 (24.2%)	17 (19.5%)
Constipation	5 (5.4%)	9 (9.5%)	4 (4.6%)
Decreased appetite	7 (7.5%)	2 (2.1%)	4 (4.6%)
Diarrhea	7 (7.5%)	3 (3.2%)	7 (8.0%)
Dyspepsia	6 (6.5%)	9 (9.5%)	4 (4.6%)
Tooth disorder	5 (5.4%)	2 (2.1%)	2 (2.3%)
Vomiting	3 (3.2%)	7 (7.4%)	6 (6.9%)
Abdominal pain	10 (10.8%)	7 (7.4%)	10 (11.5%)
Nervous system			
Dizziness	22 (23.7%)	45 (47.4%)	16 (18.4%)
Emotional lability	6 (6.5%)	3 (3.2%)	1 (1.1%)
Hostility	7 (7.5%)	3 (3.2%)	0 (0%)
Insomnia	14 (15.1%)	13 (13.7%)	4 (4.6%)
Nervousness	8 (8.6%)	6 (6.3%)	5 (5.7%)

Somnolence	16 (17.2%)	13 (13.7%)	3 (3.4%)
Tremor	10 (10.8%)	14 (14.7%)	2 (2.3%)
Headache	32 (34.4%)	38 (40.0%)	34 (39.1%)
Respiratory system			
Cough increased	5 (5.4%)	3 (3.2%)	6 (6.9%)
Pharyngitis	5 (5.4%)	12 (12.6%)	8 (9.2%)
Respiratory disorder	10 (10.8%)	7 (7.4%)	11 (12.6%)
Rhinitis	7 (7.5%)	3 (3.2%)	5 (5.7%)
Sinusitis	6 (6.5%)	2 (2.1%)	7 (8.0%)
Other			
Sweating	1 (1.1%)	6 (6.3%)	1 (1.1%)
Abnormal vision	1 (1.1%)	7 (7.4%)	2 (2.3%)
Asthenia	10 (10.8%)	7 (7.4%)	10 (11.5%)
Back pain	4 (4.3%)	2 (2.1%)	10 (11.5%)
Infection	10 (10.8%)	5 (5.3%)	9 (10.3%)
Trauma	2 (2.2%)	3 (3.2%)	6 (6.9%)




Figure 1. Of 425 adolescents who were screened, 275 fulfilled criteria for major depression and were randomized to receive 8 weeks of treatment with paroxetine (93 subjects), imipramine (95 subjects), or placebo (87 subjects). A total of 69% of subjects (N=190) completed the trial. Withdrawal rates were 28% for paroxetine, 40% for imipramine, and 24% for placebo.

WB 202493




Figure 2. Percentage of paroxetine, imipramine, and placebo-treated subjects achieving remission in the last-observation carried forward and completer subgroups (ie, HAMD total score ≤ 8). * $P=.019$; NS = $P \geq .440$.

WB 202494